PARPi after PARPi in epithelial ovarian cancer [PDF]
Gynecologic Oncology Reports, 2021 The objective of this study was to describe the treatment experience of patients with recurrent epithelial ovarian cancer who are retreated with an inhibitor of poly(ADP-ribose)-polymerase (PARPi). We conducted a multi-institutional, retrospective review
K.G. Essel +8 more
doaj +8 more sources
GIInger Predicts Homologous Recombination Deficiency and Patient Response to PARPi Treatment From Shallow Genomic Profiles [PDF]
Cell Reports Medicine, 2023 International audienceHighlights d Implementation hurdles restrict adoption of HRD testing, a PARPi response biomarker d GIInger leverages HRD-induced genome scarring from lowcoverage sequencing data d GIInger accurately stratifies ovarian cancer ...
Ana Claudia Marques, Ewan Smith
exaly +2 more sources
Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer. [PDF]
Clin Transl MedClinical and Translational Medicine, Volume 16, Issue 11, November 2026.
Perez JM +3 more
europepmc +2 more sources
Establishment and Molecular Characterization of an in Vitro Model for PARPi-Resistant Ovarian Cancer
Cancers, 2023 Overcoming PARPi resistance is a high clinical priority. We established and characterized comparative in vitro models of acquired PARPi resistance, derived from either a BRCA1-proficient or BRCA1-deficient isogenic background by long-term exposure to ...
Anna Dubrovska +2 more
exaly +2 more sources
Gynecologic Oncology Reports, 2022 Introduction: We aimed to evaluate real-life experiences with the re-challenge of poly(ADP-Ribose)Polymerase (PARP) inhibitors (PARPi) after a prior PARPi therapy in patients with recurrent EOC. Methods: A retrospective descriptive study was conducted at
Thaïs Baert +2 more
exaly +3 more sources
Bipolar Androgen Therapy as a Potential Mechanistic Bridge to Enhance PARP Inhibitor Efficacy in Prostate Cancer. [PDF]
Kaohsiung J Med SciABSTRACT Prostate cancer remains a leading cause of cancer‐related mortality, largely driven by progression to metastatic castration‐resistant prostate cancer (mCRPC). Although poly(ADP‐ribose) polymerase inhibitors (PARPis) have improved outcomes in patients with homologous recombination repair (HRR) alterations, particularly in BRCA2‐mutated disease,
Jhan JH +4 more
europepmc +2 more sources
Safety and tolerability of PARP inhibitors in cancer patients: a network meta-analysis of randomized controlled trials [PDF]
BMC CancerBackground Poly(ADP-ribose) polymerase inhibitors (PARPi) for the treatment of homologous recombination (HR)-deficient cancers have revolutionized cancer treatment in recent years. Despite documented clinical benefits, the use of PARPi is associated with
Chenyu Wei +4 more
doaj +2 more sources
Journal of Translational MedicineBackground Ovarian cancer (OC) often presents at advanced stages with poor prognosis. Although poly(ADP-ribose) polymerase inhibitors (PARPi) offer clinical benefits, resistance remains a major challenge.
Huimin Xiao +9 more
doaj +2 more sources
Expert Review of Anticancer Therapy, 2022 Poly (ADP-ribose) polymerase inhibitors (PARPi) have been approved for the treatment of advanced tumors with defects in genes involved in homologous recombination repair (HRR), including cancers of the prostate, pancreas, breast, and ovary.
Dachun Jin
exaly +2 more sources
Efficacy of Chemotherapy After Progression During or Following PARPi Exposure in Ovarian Cancer☆
ESMO OpenInternational audiencePoly(ADP-ribose) polymerase inhibitors (PARPis) improved advanced ovarian cancer treatment. Most patients progress during or following PARPi exposure, however, with concerns about sensitivity of subsequent ...
Jean-Sébastien Frénel +2 more
exaly +2 more sources